KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma

Journal of Immunology

Volumn 192, Issue 4, 2014, Pages 1954-1961

  Malaisé, Muriel ^a   Rovira, Jordi ^a,b   Renner, Philipp ^a   Eggenhofer, Elke ^a   Sabet Baktach, Manije ^a   Lantow, Margareta ^a   Lang, Sven A ^a   Koehl, Gudrun E ^a   Farkas, Stefan A ^a   Loss, Martin ^a   Agha, Ayman ^a   Campistol, Josep M ^b   Schlitt, Hans J ^a   Geissler, Edward K ^a   Kroemer, Alexander ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; EOMESODERMIN; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; LYMPHOCYTE RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY G1; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; COLORECTAL CARCINOMA; COMPLEX FORMATION; CONTROLLED STUDY; IN VIVO STUDY; LUNG METASTASIS; LYMPHOCYTE ACTIVATION; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; TUMOR IMMUNITY;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD27; CELL DIFFERENTIATION; CELLS, CULTURED; COLORECTAL NEOPLASMS; HOMEODOMAIN PROTEINS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-15; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PORE FORMING CYTOTOXIC PROTEINS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, INTERLEUKIN-15; RECOMBINANT FUSION PROTEINS; T-BOX DOMAIN PROTEINS;

EID: 84896713527     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300876     Document Type: Article

References (46)

1. Edwards, B. K., E. Ward, B. A. Kohler, C. Eheman, A. G. Zauber, R. N. Anderson, A. Jemal, M. J. Schymura, I. Lansdorp-Vogelaar, L. C. Seeff, et al. 2010. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116: 544-573.
2. Jemal, A., R. Siegel, E. Ward, T. Murray, J. Xu, C. Smigal, and M. J. Thun. 2006. Cancer statistics, 2006. CA Cancer J. Clin. 56: 106-130.
3. O'Connell, J. B., M. A. Maggard, and C. Y. Ko. 2004. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl. Cancer. Inst. 96: 1420-1425.
4. Staib, L., K. H. Link, A. Blatz, and H. G. Beger. 2002. Surgery of colorectal cancer: surgical morbidity and five- and ten-year results in 2400 patients - monoinstitutional experience. World J. Surg. 26: 59-66.
5. Koebel, C. M., W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig, L. J. Old, M. J. Smyth, and R. D. Schreiber. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450: 903-907.
6. Kärre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678.
7. Smyth, M. J., K. Y. Thia, E. Cretney, J. M. Kelly, M. B. Snook, C. A. Forbes, and A. A. Scalzo. 1999. Perforin is a major contributor to NK cell control of tumor metastasis. J. Immunol. 162: 6658-6662.
8. Kim, S., K. Iizuka, H. L. Aguila, I. L. Weissman, and W. M. Yokoyama. 2000. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl. Acad. Sci. USA 97: 2731-2736.
9. Platonova, S., J. Cherfils-Vicini, D. Damotte, L. Crozet, V. Vieillard, P. Validire, P. André, M. C. Dieu-Nosjean, M. Alifano, J. F. Régnard, et al. 2011. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 71: 5412-5422.
10. Eckl, J., A. Buchner, P. U. Prinz, R. Riesenberg, S. I. Siegert, R. Kammerer, P. J. Nelson, and E. Noessner. 2012. Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J. Mol. Med. (Berl.) 90: 55-66.
11. Halama, N., M. Braun, C. Kahlert, A. Spille, C. Quack, N. Rahbari, M. Koch, J. Weitz, M. Kloor, I. Zoernig, et al. 2011. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin. Cancer Res. 17: 678-689.
12. Coca, S., J. Perez-Piqueras, D. Martinez, A. Colmenarejo, M. A. Saez, C. Vallejo, J. A. Martos, and M. Moreno. 1997. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79: 2320-2328.
13. Kondo, E., K. Koda, N. Takiguchi, K. Oda, K. Seike, M. Ishizuka, and M. Miyazaki. 2003. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig. Surg. 20: 445-451.
14. Wang, J. H., A. Nichogiannopoulou, L. Wu, L. Sun, A. H. Sharpe, M. Bigby, and K. Georgopoulos. 1996. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 5: 537-549.
15. Colucci, F., S. I. Samson, R. P. DeKoter, O. Lantz, H. Singh, and J. P. Di Santo. 2001. Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells. Blood 97: 2625-2632.
16. Yokota, Y., A. Mansouri, S. Mori, S. Sugawara, S. Adachi, S. Nishikawa, and P. Gruss. 1999. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 397: 702-706.
17. Ikawa, T., S. Fujimoto, H. Kawamoto, Y. Katsura, and Y. Yokota. 2001. Commitment to natural killer cells requires the helix-loop-helix inhibitor Id2. Proc. Natl. Acad. Sci. USA 98: 5164-5169.
18. Townsend, M. J., A. S. Weinmann, J. L. Matsuda, R. Salomon, P. J. Farnham, C. A. Biron, L. Gapin, and L. H. Glimcher. 2004. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity 20: 477-494.
19. Robbins, S. H., M. S. Tessmer, L. Van Kaer, and L. Brossay. 2005. Direct effects of T-bet and MHC class I expression, but not STAT1, on peripheral NK cell maturation. Eur. J. Immunol. 35: 757-765.
20. Gordon, S. M., J. Chaix, L. J. Rupp, J. Wu, S. Madera, J. C. Sun, T. Lindsten, and S. L. Reiner. 2012. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 36: 55-67.
21. Werneck, M. B., G. Lugo-Villarino, E. S. Hwang, H. Cantor, and L. H. Glimcher. 2008. T-bet plays a key role in NK-mediated control of melanoma metastatic disease. J. Immunol. 180: 8004-8010.
22. Gill, S., A. E. Vasey, A. De Souza, J. Baker, A. T. Smith, H. E. Kohrt, M. Florek, K. D. Gibbs, Jr., K. Tate, D. S. Ritchie, and R. S. Negrin. 2012. Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood 119: 5758-5768.
23. Peng, S. L., M. J. Townsend, J. L. Hecht, I. A. White, and L. H. Glimcher. 2004. T-bet regulates metastasis rate in a murine model of primary prostate cancer. Cancer Res. 64: 452-455.
24. Jenne, C. N., A. Enders, R. Rivera, S. R. Watson, A. J. Bankovich, J. P. Pereira, Y. Xu, C. M. Roots, J. N. Beilke, A. Banerjee, et al. 2009. T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J. Exp. Med. 206: 2469-2481.
25. Chiossone, L., J. Chaix, N. Fuseri, C. Roth, E. Vivier, and T. Walzer. 2009. Maturation of mouse NK cells is a 4-stage developmental program. Blood 113: 5488-5496.
26. Hayakawa, Y., and M. J. Smyth. 2006. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J. Immunol. 176: 1517-1524.
27. Huntington, N. D., H. Tabarias, K. Fairfax, J. Brady, Y. Hayakawa, M. A. Degli-Esposti, M. J. Smyth, D. M. Tarlinton, and S. L. Nutt. 2007. NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J. Immunol. 178: 4764-4770.
28. Soderquest, K., N. Powell, C. Luci, N. van Rooijen, A. Hidalgo, F. Geissmann, T. Walzer, G. M. Lord, and A. Martín-Fontecha. 2011. Monocytes control natural killer cell differentiation to effector phenotypes. Blood 117: 4511-4518.
29. DiSanto, J. P., W. Müller, D. Guy-Grand, A. Fischer, and K. Rajewsky. 1995. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc. Natl. Acad. Sci. USA 92: 377-381.
30. Lodolce, J. P., D. L. Boone, S. Chai, R. E. Swain, T. Dassopoulos, S. Trettin, and A. Ma. 1998. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9: 669-676.
31. Ranson, T., C. A. Vosshenrich, E. Corcuff, O. Richard, V. Laloux, A. Lehuen, and J. P. Di Santo. 2003. IL-15 availability conditions homeostasis of peripheral natural killer T cells. Proc. Natl. Acad. Sci. USA 100: 2663-2668.
32. Ranson, T., C. A. Vosshenrich, E. Corcuff, O. Richard, W. Müller, and J. P. Di Santo. 2003. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 101: 4887-4893.
33. Steel, J. C., T. A. Waldmann, and J. C. Morris. 2012. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 33: 35-41.
34. Wege, A. K., W. Ernst, J. Eckl, B. Frankenberger, A. Vollmann-Zwerenz, D. N. Männel, O. Ortmann, A. Kroemer, and G. Brockhoff. 2011. Humanized tumor mice - a new model to study and manipulate the immune response in advanced cancer therapy. Int. J. Cancer 129: 2194-2206.
35. Kroemer, A., X. Xiao, N. Degauque, K. Edtinger, H. Wei, G. Demirci, and X. C. Li. 2008. The innate NK cells, allograft rejection, and a key role for IL-15. J. Immunol. 180: 7818-7826.
36. Yang, Q., M. E. Hokland, J. L. Bryant, Y. Zhang, U. Nannmark, S. C. Watkins, R. H. Goldfarb, R. B. Herberman, and P. H. Basse. 2003. Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases. Int. J. Cancer 105: 512-519.
37. Kobayashi, H., S. Dubois, N. Sato, H. Sabzevari, Y. Sakai, T. A. Waldmann, and Y. Tagaya. 2005. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 105: 721-727.
38. Yu, P., J. C. Steel, M. Zhang, J. C. Morris, and T. A. Waldmann. 2010. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin. Cancer Res. 16: 6019-6028.
39. Zhang, M., W. Ju, Z. Yao, P. Yu, B. R. Wei, R. M. Simpson, R. Waitz, M. Fassò, J. P. Allison, and T. A. Waldmann. 2012. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. J. Immunol. 188: 6156-6164.
40. Yu, P., J. C. Steel, M. Zhang, J. C. Morris, R. Waitz, M. Fasso, J. P. Allison, and T. A. Waldmann. 2012. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc. Natl. Acad. Sci. USA 109: 6187-6192.
41. Dubois, S., H. J. Patel, M. Zhang, T. A. Waldmann, and J. R. Müller. 2008. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J. Immunol. 180: 2099-2106.
42. Rovira, J., M. Sabet-Baktach, E. Eggenhofer, M. Lantow, G. E. Koehl, H. J. Schlitt, J. M. Campistol, E. K. Geissler, and A. Kroemer. 2013. A colorcoded reporter model to study the effect of immunosuppressants on CD8+ T-cell memory in antitumor and alloimmune responses. Transplantation 95: 54-62.
43. Elpek, K. G., M. P. Rubinstein, A. Bellemare-Pelletier, A. W. Goldrath, and S. J. Turley. 2010. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proc. Natl. Acad. Sci. USA 107: 21647-21652.
44. Intlekofer, A. M., N. Takemoto, E. J. Wherry, S. A. Longworth, J. T. Northrup, V. R. Palanivel, A. C. Mullen, C. R. Gasink, S. M. Kaech, J. D. Miller, et al. 2005. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 6: 1236-1244.
45. Hsieh, C. S., S. E. Macatonia, A. O'Garra, and K. M. Murphy. 1995. T cell genetic background determines default T helper phenotype development in vitro. J. Exp. Med. 181: 713-721.
46. Dubois, S., J. Mariner, T. A. Waldmann, and Y. Tagaya. 2002. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17: 537-547.